Seres Therapeutics, Inc. (MCRB)

Market Cap	139.38M
Revenue (ttm)	126.85M
Net Income (ttm)	-82.68M
Shares Out	151.45M
EPS (ttm)	-0.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,848,220
Open	0.924
Previous Close	0.924
Day's Range	0.901 - 0.999
52-Week Range	0.540 - 6.260
Beta	2.14
Analysts	Buy
Price Target	5.81 (+531.59%)
Earnings Date	May 8, 2024

About MCRB

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 26, 2015
• Employees: 233
• Stock Exchange: NASDAQ
• Ticker Symbol: MCRB

Financial Performance

In 2023, MCRB's revenue was $126.33 million, an increase of 1672.24% compared to the previous year's $7.13 million. Losses were -$113.72 million, -54.54% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for MCRB stock is "Buy." The 12-month stock price forecast is $5.81, which is an increase of 531.59% from the latest price.

Price Target

$5.81

(531.59% upside)

Analyst Consensus: Buy